Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.

What's Your Reaction?









